Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Cybulski, D. Wokołorczyk, A. Jakubowska, T. Huzarski, T. Byrski, J. Gronwald, B. Masojć, Tadeusz Deebniak, B. Górski, P. Blecharz, S. Narod, J. Lubiński (2011)
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 28
M. Carlo, Semanti Mukherjee, D. Mandelker, J. Vijai, Y. Kemel, Liying Zhang, A. Knezevic, S. Patil, O. Ceyhan-Birsoy, Kuo-Cheng Huang, A. Redzematovic, D. Coskey, Carolyn Stewart, Nisha Pradhan, A. Arnold, A. Hakimi, Ying-bei Chen, J. Coleman, D. Hyman, M. Ladanyi, K. Cadoo, M. Walsh, Z. Stadler, Chung-Han Lee, D. Feldman, M. Voss, M. Robson, R. Motzer, K. Offit (2018)
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell CarcinomaJAMA Oncology, 4
C. Cybulski, D. Wokołorczyk, J. Kładny, Grzegorz Kurzwaski, J. Suchy, E. Grabowska, J. Gronwald, T. Huzarski, T. Byrski, B. Górski, Tadeusz Dbniak, S. Narod, J. Lubiński (2007)
Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?European Journal of Human Genetics, 15
C. Cybulski, B. Górski, T. Huzarski, B. Masojć, M. Mierzejewski, T. Dębniak, U. Teodorczyk, T. Byrski, J. Gronwald, Joanna Matyjasik, E. Złowocka, M. Lenner, E. Grabowska, Katarzyna Nej, Jennifer Castañeda, K. Mȩdrek, A. Szymańska, J. Szymańska, G. Kurzawski, Janina Suchy, O. Oszurek, A. Witek, S. Narod, J. Lubiński (2004)
CHEK2 is a multiorgan cancer susceptibility gene.American journal of human genetics, 75 6
Letters prove survival for newly diagnosed metastatic non–small cell founder alleles: 1 missense mutation (I157T) and 3 truncating 5,6 lung cancer and prostate cancer. It is likely that this treat- mutations (1100delC, IVS2 + 1G>A, del5395). The I157T allele ment approach would work for other disease sites. Our study was present in 78 participants with renal cancer and 410 generated a hypothesis that suggests that prospective trials control participants (odds ratio [OR], 2.0; 95% CI, 1.6-2.6; evaluating definitive pelvic RT for newly diagnosed meta- P < .001) (unpublished data, 2018). A truncating mutation static cervical cancer are warranted. Although definitive evi- was present in 20 participants and 80 control participants dence is lacking, the choice of pelvic RT remains at the discre- (OR, 2.5; 95% CI, 1.5-4.1; P = .0003) (unpublished data, tion of the treating physician, who considers performance 2018). Unlike the situation for breast cancer, but similar to status, metastatic disease burden, radiation adverse effects and the situation for colon cancer, the risk of cancer associated the patient’s preference. with the missense allele was similar to that of the truncating alleles. In Poland, the number of I157T mutations in patients with renal cancer outnumbered the 1100delC mutations
JAMA Oncology – American Medical Association
Published: Apr 28, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.